Singapore Institute of Advanced Medicine (SGX:9G2) loss after tax and total comprehensive loss from continuing operations for the six moths ended June 30 widened 67% year over year to SG$16.2 million from SG$9.7 million, a filing with the Singapore Exchange said on Tuesday.
Revenue remained relatively unchanged at SG$8.1 million for the period despite increase in revenue from radiation therapy and medical oncology services.
Shares of the medical services company plunged nearly 15% in recent trading.
Price (SGD): S$67.60, Change: S$+0.39, Percent Change: +0.58%
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。